Monopar Therapeutics (MNPR) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending September 2025, Monopar Therapeutics (NASDAQ:MNPR) is held by 56 institutional firms.

• Institutional ownership in Monopar Therapeutics edged up to 70.3% in September 2025, compared to 51.8% in June 2025.
• The company experienced a 40.57% quarterly change in institutional shares held, alongside an increase of 833.33% in total owners annually.
• During the quarter, 33 institutions bought more Monopar Therapeutics shares, 16 sold shares, and 7 of the 56 total investors held their position steady.
• Collectively, institutional investors increased their stake in Monopar Therapeutics to 4.34Mn shares as of September 2025, a change that is up by 1.25Mn shares quarter on quarter and up 4.32Mn shares year over year.
• The top institutional stake in Monopar Therapeutics as of September 30, 2025 belongs to JANUS HENDERSON GROUP PLC, which owns 1.29Mn shares, or 20.87% of the company.
• Among the most significant buyers of Monopar Therapeutics during September 2025 were WELLINGTON MANAGEMENT GROUP LLP (231.46K), DEERFIELD MANAGEMENT COMPANY, L.P. (159.76K), Saturn V Capital Management LP (155.37K), TCG Crossover Management, LLC (153.00K), VANGUARD GROUP INC (121.73K).
• Leading sellers of Monopar Therapeutics stock in September 2025 included UBS Group AG (13.90K), GEODE CAPITAL MANAGEMENT, LLC (11.96K), GOLDMAN SACHS GROUP INC (11.96K), MILLENNIUM MANAGEMENT LLC (7.46K), NORTHERN TRUST CORP (4.96K).
• The top 10 institutional holders of Monopar Therapeutics for the quarter ending September 2025 included JANUS HENDERSON GROUP PLC (1.29Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (659.20K), RA CAPITAL MANAGEMENT, L.P. (511.21K), WELLINGTON MANAGEMENT GROUP LLP (231.46K), VANGUARD GROUP INC (208.22K), BlackRock, Inc. (203.75K), DEERFIELD MANAGEMENT COMPANY, L.P. (159.76K), Saturn V Capital Management LP (155.37K), TCG Crossover Management, LLC (153.00K), ADAR1 Capital Management, LLC (130.00K).